Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double Blind Placebo Controlled Dose Ranging Study for the Assessment of Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single Ascending Subcutaneous and Oral Doses of GLPG0187 in Healthy Subjects.

Next Previous
Trial Profile

Double Blind Placebo Controlled Dose Ranging Study for the Assessment of Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single Ascending Subcutaneous and Oral Doses of GLPG0187 in Healthy Subjects.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jan 2010

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GLPG 0187 (Primary) ; GLPG 0187 (Primary)
  • Indications Breast cancer; Cancer metastases; Prostate cancer
  • Focus Adverse reactions; Biomarker
  • Sponsors Galapagos NV

Most Recent Events

  • 19 Jan 2010 Status changed from active, no longer recruiting to completed as reported in a Galapagos NV media release.
  • 19 Jan 2010 Favourable tolerability results have been reported in a Galapagos NV media release.
  • 03 Oct 2009 Planned end date changed from 1 Oct 2009 to 1 Dec 2009 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top